Inhibitory mechanisms by which suramin may attenuate neointimal formation after balloon angioplasty

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 6, 1999, Pages 960-971

  Gray, Timothy J ^a,c   Strauss, Bradley H ^b,c   Hinek, Aleksander ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angioplasty; Elastin receptor; Restenosis; Suramin

Indexed keywords

BINDING PROTEIN; ELASTIN; FIBRONECTIN; INTERLEUKIN 1BETA; SURAMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EXTRACELLULAR MATRIX; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; RESTENOSIS; SMOOTH MUSCLE FIBER; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL MOVEMENT; CORONARY DISEASE; DNA; ELASTIN; FIBRONECTINS; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MALE; MUSCLE, SMOOTH, VASCULAR; NUCLEOTIDE MAPPING; PROTEIN BINDING; RABBITS; RECEPTORS, CELL SURFACE; SURAMIN; TUNICA INTIMA;

EID: 0033017537     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199906000-00018     Document Type: Article

References (65)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal angioplasty. N Engl J Med 1979;301:61-8.
2. Detre K, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981: The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988; 318:265-70.
3. Cowley MJ, Dorros G, Kelsey SF, VanRaden M, Detre KM. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;53:12C-5C.
4. Hollman J, Gruentzig AR, Douglas JS, King SB III, Ischinger T, Meier B. Acute occlusion after percutaneous transluminal coronary angioplasty: a new approach. Circulation 1983;68:725-32.
5. Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful angioplasty in patients with single-vessel disease. Circulation 1986;73:710-7.
6. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, and 3 months. Circulation 1988;77:361-72.
7. Macleod DC, Strauss BH, De Jong M, et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994;23:59-65.
8. Kimura T, Kaburagi S, Tamura T, et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherotomy. Circulation 1997;96:475-83.
9. Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog Vasc Dis 1997;39:361-98.
10. Nagler A, Miao HQ, Aingorn H, Pines M, Genina O, Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 1997;17:194-202.
11. Asada Y, Tsuneyoshi A, Marutsuka K, Sumiyoshi A. Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo. Cardiovasc Res 1994;28:1166-9.
12. Semashko DC, Cooper MR, Myers CE, Aaronson SA, Bush HL. Suramin inhibition of smooth muscle cell proliferation in vitro and intimai hyperplasia in vivo in a nonhuman primate model of deep arterial injury. Surg Forum 1991;42:351-3.
13. Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev 1994; 20:259-73.
14. LaRocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990;2:106-15.
15. Sklar GN, Eddy HA, Jacobs SC, Kyprianou N. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Ural 1993;150:1526-32.
16. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993;53:2239-48.
17. Voogd TE, Vansterkenburg ELM, Wilting J, Janssen LHM. Recent research on the biological activity of suramin. Pharmacol Rev 1993;45:177-303.
18. Middaugh CR, Mach H, Burke CJ, et al. Nature of the interaction of the growth factors with suramin. Biochemistry 1992;31:9016-24.
19. Van Oosterom AT, De Smedt EA, Denis LJ, de Bruijn EA, Mahler C. Suramin for prostatic cancer: a Phase I/II study in advanced extensively pretreated disease. Eur J Cancer 1990;26:422-8.
20. Henesey C, Boscoboinik D, Assi A. Suramin, anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 1998;258:156-8.
21. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-73.
22. Strassman G, D'Alessandro F, Fong M, Nordan RP, Nickel P, Chizzonite R. Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities. Int J Immunopharmacol 1994;16:931-9.
23. Coffey RJ, Leof EB, Shipley GD, Moses HL. Suramin inhibition of growth factor receptor binding and mutagenicity in AKR 2B cells. J Cell Physiol 1987;132:143-8.
24. Schiller C, Spittler A, Willheim M, et al. Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on the phagocytic properties. Immunology 1994;81:598-604.
25. Strassmann G, Graber N, Goyert SM, et al. Inhibition of lipopolysaccharide and IL-1 but not of TNF-induced activation of human endothelial cells by suramin. J Immunol 1994;153:2239-47.
26. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimai proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75.
27. Home MK, Stein CA, LaRocca RV, Myers CE. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood 1988;71:273-9.
28. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA. Suramin, a potent inhibitor of melanoma heparanase invasion. J Biol Chem 1990;266:9661-6.
29. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells: correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994;93:788-98.
30. Sjolund M, Thyberg J. Suramin inhibits binding and degradation of platelet-derived growth factor in arterial smooth muscle cells but does not interfere with autocrine stimulation of DNA synthesis. Cell Tissue Res 1989;256:35-43.
31. Hinek A. Biological functions of the non-integrin elastin/laminin receptor. Biol Chem 1996;377:471-80.
32. Hinek A, Boyle J, Rabinovitch M. Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced "shedding" of the 67-kDa cell surface elastin binding protein. Exp Cell Res 1992;203:344-53.
33. Hinek A, Molossi S, Rabinovitch M. Functional interplay between interleukin-1 receptor and elastin binding protein controls fibronectin synthesis in coronary artery smooth muscle cells. Exp Cell Res 1996;225:122-31.
34. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodelling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994;75: 650-8.
35. Ross R. The smooth muscle cell II: growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971;50:172-9.
36. Durante W, Liao L, Iftikhar I, Cheng K, Schafer AI. Platelet-derived growth factor regulates vascular smooth muscle cell proliferation by inducing cationic amino acid transporter gene expression. J Biol Chem 1996;271:11838-43.
37. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996;78:225-30.
38. Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984;118:253-6.
39. Boudreau N, Turley EA, Rabinovitch M. Fibronectin, hyaluronan and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration. Dev Biol 1991;143:235-47.
40. Molossi S, Clausell N, Rabinovitch M. Coronary artery endothelial interleukin-1B mediates enhanced fibronectin production related to post-cardiac transplant arteriopathy in piglets. Circulation 1993; 88:248-56.
41. Molossi S, Clausell N, Rabinovitch M. Reciprocal induction of tumor necrosis factor-α and interleukin-1 B activity mediates fibronectin in coronary artery smooth muscle cells. J Cell Physiol 1995; 163:19-29.
42. Clausell N, Molossi S, Rabinovitch M. Increased interleukin-1B and fibronectin expression are early features of the development of the post-cardiac transplant coronary arteriopathy in piglets. Am J Pathol 1993;142:1772-86.
43. Balkwill F, Burke F. The cytokine network. Immunol Today 1989; 10:299-304.
44. Nilsson J. Cytokines and smooth muscle cells in atherosclerosis. Cardiovasc Res 1993;27:1184-90.
45. Ross R. Atherosclerosis: a defense mechanism gone awry. Am J Pathol 1993;143:987-1002.
46. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
47. Russell M, Fujita M, Masek M, Rowan R, Billingham M. Cardiac graft vascular disease: nonselective involvement of large and small vessels. Transplantation 1993;56:762-4.
48. Billingham M. Histopathology of graft coronary disease. J Heart Lung Transplant 1992;11:38-44.
49. Raines E, Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 1993;69:30-7.
50. Cassels W. Migration of smooth muscle cells: critical events in restenosis. Circulation 1992;86:723-9.
51. Hinek A, Rabinovitch M, Keeley FW, Okamura-Oho J, Callahan JW. The 67-kD elastin/laminin-binding protein is related to an enzymatically inactive, alternatively-spliced variant of β-galactosidase. J Clin Invest 1993;91:1198-205.
52. Hinek A. Nature and the multiple functions of the 67-kD elastin-/ laminin binding protein. Cell Adhes Comm 1994;2:185-93.
53. Hinek A, Wrenn DS, Mecham RP, Barondes SH. The elastin receptor: a galactosidase-binding protein. Science 1988;239:1539-41.
54. Hinek A, Mecham RP, Keeley FW, Rabinovitch M. Impaired elastin fiber assembly is related to reduced 67-kD elastin binding protein in fetal lamb ductus arteriosus and in cultured aortic smooth muscle cells treated with chondroitin sulfate. J Clin Invest 1991; 88:2083-94.
55. Huang SS, Huang JS. Rapid turnover of the platelet-derived growth factor receptor in cis-transformed cells and reversal by suramin: implications for the mechanism of autocrine transformation. J Biol Chem 1988;263:12608-18.
56. Moscatelli D, Quarto N. Transformation of NIH3T3 cells with basic fibroblast growth factor receptor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol 1989;109:2519-27.
57. Hinek A, Keeley FW, Callahan JW. Recycling of the 67-kD elastin binding protein in arterial myocytes is imperative for secretion of tropoelastin. Exp Cell Res 1995;220:312-24.
58. Larsen AK. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol 1993;32:96-8.
59. Crowley ST, Ray CJ, Nawaz D, Majack RA, Horwitz LD. Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am J Pliysiol 1995;269:H1641-7.
60. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988;107:1199-205.
61. Presta M, Tiberio I, Rusnati M, Dell'Era P, Ragnotti G. Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. Cell Regul 1991;2:719-26.
62. Clausell N, Rabinovitch M. Upregulation of fibronectin synthesis by interleukin-1B in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets. J Clin Invest 1993;92:1850-8.
63. Clausell N, Correa de Lima V, Molossi S, et al. Expression of tumor necrosis factor α and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 1995;73:534-9.
64. Stadius ML, Rowan R, Fleischauer JF, Kernoff R, Billingham M, Gown AA. Time course and cellular characteristics of iliac artery response to acute balloon injury: an angiographie, morphometric, and immunocytochemical analysis in the cholesterol-fed New Zealand White rabbit. Arterioscler Thromb 1992;12:1267-73.
65. Libby P, Salomon R, Payne D, Schoen F, Pober J. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc 1989;21: 3677-84.